Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

OBJECTIVE: To evaluate the efficacy and safety of CT-P10, a rituximab biosimilar after a single switch, during a multinational, randomized, double-blind Phase 3 trial involving patients with RA. METHODS: Patients received 48 weeks’ treatment with CT-P10 or United States- or European Union-sourced re...

Descripción completa

Detalles Bibliográficos
Autores principales: Shim, Seung Cheol, Božić-Majstorović, Ljubinka, Berrocal Kasay, Alfredo, El-Khouri, Elias Chalouhi, Irazoque-Palazuelos, Fedra, Cons Molina, Francisco Fidencio, Medina-Rodriguez, Francisco G, Miranda, Pedro, Shesternya, Pavel, Chavez-Corrales, Jose, Wiland, Piotr, Jeka, Slawomir, Garmish, Olena, Hrycaj, Pawel, Fomina, Natalia, Park, Won, Suh, Chang-Hee, Lee, Sang Joon, Lee, Sung Young, Bae, Yun Ju, Yoo, Dae Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880852/
https://www.ncbi.nlm.nih.gov/pubmed/31184752
http://dx.doi.org/10.1093/rheumatology/kez152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880852/
https://www.ncbi.nlm.nih.gov/pubmed/31184752
http://dx.doi.org/10.1093/rheumatology/kez152

Ejemplares similares